NKGen Biotech (NYSE:NKGN – Get Free Report) and Candel Therapeutics (NASDAQ:CADL – Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, analyst recommendations, valuation, profitability, institutional ownership, risk and earnings.
Risk and Volatility
NKGen Biotech has a beta of 0.53, meaning that its share price is 47% less volatile than the S&P 500. Comparatively, Candel Therapeutics has a beta of -0.88, meaning that its share price is 188% less volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of current ratings for NKGen Biotech and Candel Therapeutics, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| NKGen Biotech | 0 | 0 | 0 | 0 | 0.00 |
| Candel Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Earnings and Valuation
This table compares NKGen Biotech and Candel Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| NKGen Biotech | $80,000.00 | 118.90 | -$82.94 million | ($5.08) | -0.05 |
| Candel Therapeutics | $120,000.00 | 1,291.22 | -$37.94 million | ($1.69) | -2.86 |
Candel Therapeutics has higher revenue and earnings than NKGen Biotech. Candel Therapeutics is trading at a lower price-to-earnings ratio than NKGen Biotech, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
76.2% of NKGen Biotech shares are held by institutional investors. Comparatively, 13.9% of Candel Therapeutics shares are held by institutional investors. 74.7% of NKGen Biotech shares are held by insiders. Comparatively, 41.6% of Candel Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Profitability
This table compares NKGen Biotech and Candel Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| NKGen Biotech | N/A | N/A | -479.36% |
| Candel Therapeutics | N/A | -629.29% | -134.23% |
Summary
Candel Therapeutics beats NKGen Biotech on 8 of the 13 factors compared between the two stocks.
About NKGen Biotech
NKGen Biotech, Inc. operates as a clinical-stage biotechnology company that focuses on the development and commercialization of autologous, allogeneic, and CAR-NK natural killer cell therapies. It develops SNK01, an autologous NK cell therapy; and SNK02, an allogeneic NK cell therapy, which are in Phase 1 clinical trials. The company was founded in 2017 and is based in Santa Ana, California.
About Candel Therapeutics
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the?enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.
Receive News & Ratings for NKGen Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NKGen Biotech and related companies with MarketBeat.com's FREE daily email newsletter.
